We have both prevention and symptomatic trials. Our current prevention trial is listed at the top, followed by our symptomatic trials.
The purpose of this clinical trial is to evaluate the efficacy, safety and tolerability of solaneuzumab, a drug that may have the potential to slow the onset of Alzheimer's disease (AD).
The purpose of the EARLY Trial is to evaluate the safety and efficacy of an investigational medication in people at risk of developing Alzheimer’s disease dementia.
The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as compared with placebo in participants with early AD.